Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging
Grażyna Lietzau, Giulia Magni, Ján Kehr, Takashi Yoshitake, Emanuel Candeias, Ana I. Duarte, Hans Pettersson, Josefin Skogsberg, Maria P. Abbracchio, Thomas Klein, Thomas Nyström, Stefania Ceruti, Vladimer Darsalia, Cesare Patrone
Topics & Concepts
LinagliptinDopaminergicMicrodialysisGlimepirideInternal medicineNeuroprotectionEndocrinologyDopamineType 2 diabetesDipeptidyl peptidase-4Diabetes mellitusNigrostriatal pathwayMedicineDipeptidyl peptidasePharmacologyBiologySubstantia nigraBiochemistryEnzymePeptidase Inhibition and AnalysisDiabetes Treatment and ManagementAdenosine and Purinergic Signaling